Through the short film ‘Thank You,’ featuring real patients, the campaign highlights the impact of in vitro diagnostics (IVD), which plays a key role in 70% of medical decisions worldwide and is crucial to patient survival and quality of lifeThe launch coincides with the company’s 60th anniversary, consolidating a six-decade trajectory to international leadership across its five clinical areas of specialized diagnostics

BARCELONA, Spain, Nov. 12, 2026 /PRNewswire/ — In Vitro Diagnostics (IVD) plays a crucial role in life-saving clinical decisions. To recognize and thank the healthcare professionals and laboratory teams who make this possible every day, Werfen has launched the ‘Thank You’ initiative. Launched on the occasion of its 60th anniversary, this is the company’s first corporate brand campaign centered entirely on its purpose of advancing patient care by delivering trusted and innovative specialized diagnostics.

Currently, IVD influences around 70% of clinical decisions worldwide, ranging from confirming compatibility in a kidney transplant to detecting chronic disease or monitoring patients during highly complex cardiac surgery. However, this analytical work largely takes place behind the scenes.

The central element in the campaign is a documentary short film, available at https://www.werfen.com/thankyou. With it, Werfen seeks to highlight the direct impact of having reliable and timely data, at the time of diagnosis and in the continuous management of diseases and people’s quality of life, focusing on improving patient outcomes through diagnostic precision.

The voice of patients and the true significance of diagnostics

The campaign gathers stories from real patients who have gone through complex health processes. Through their stories, patients express their gratitude to the healthcare professionals who interpreted their test results and provided the necessary clarity to determine the appropriate therapeutic path to manage their health.

Developed in collaboration with patient associations and non-profit organizations, the initiative gives visibility to the relevance of diagnostics in more than a dozen pathologies such as lupus, thalassemia, hemophilia, thrombosis episodes, rheumatoid arthritis, complex cardiac surgery, or kidney and liver transplants. All of them are severe medical conditions that represent Werfen’s five highly specialized clinical areas: Hemostasis, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant.

In the words of Alejandro Risso, CEO of Werfen: “Sixty years ago, Werfen was born with a calling to stand alongside healthcare professionals in moments that mark a before and after in patients’ lives. Our responsibility is to provide maximum analytical precision so that professionals can make decisions with total confidence when it matters most.” To this, he adds: “Behind every diagnosis there is knowledge, experience, precision and, above all, people committed to improving and saving lives. With this campaign we want to bring these professionals to the forefront and thank them for a work that, after 60 years, continues to give meaning to ours.”

Six decades of commitment to specialized diagnostics

The campaign launch takes place during the company’s 60-year anniversary. Founded in Barcelona in 1966, Werfen has evolved to establish itself as a multinational group specialized in IVD, with presence in more than 30 countries, as well as its own R&D capacity and production centers in Europe and the United States.

Throughout this time, the company has strengthened its international presence through direct commercial expansion in key markets such as the United States and China, coupled with the progressive integration of specialized firms in its different clinical areas. This process culminated in 2024 with the strategic decision to concentrate all its resources and research on in vitro diagnostics, thereby reaffirming its commitment to continue providing greater certainty to the scientific and medical community.

Innovation has been one of Werfen’s pillars throughout its 60-year history. As a result of this commitment, in 2025 the company allocated 190 million euros to research and development to continue driving advances in the science of in vitro diagnostics.

In a field where scientific rigor, clinical relevance, and reliability are fundamental, Werfen combines innovation, experience, and talent to offer more effective diagnostics that help laboratories, hospitals, doctors, and healthcare professionals make better clinical decisions and improve people’s quality of life.

About Werfen

Founded in 1966, Werfen is a worldwide developer, manufacturer, and distributor of specialized diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The company’s business lines include Coagulation, Acute Care Diagnostics, Transfusion, Autoimmunity, and Transplant. With a workforce of over 7,130 people, Werfen operates directly in more than 30 countries and in over 100 territories through distributors. For more information, visit werfen.com.

Legal Disclaimer 

This document contains forward-looking statements regarding our future business, financial data, and future events related to Werfen that may constitute forward-looking estimates. These estimates can be identified by words such as “expectation,” “forward-looking,” “anticipation,” “intention,” “plan,” “belief,” “seek,” “estimate,” “future,” “project,” or words of similar meaning. We may also make forward-looking estimates in other reports, presentations, and press releases. Additionally, our representatives may occasionally make oral statements with forward-looking estimates. These estimates are based on our current expectations and certain assumptions, many of which are beyond the corporation’s control and are subject to a series of risks and uncertainties. In the event that any of such risks or uncertainties materialize or underlying expectations fail to occur, Werfen’s results, performance, or achievements could vary substantially (positively or negatively) from those explicitly or implicitly described in the relevant forward-looking estimate. Werfen assumes no obligation to revise or update any forward-looking estimates previously made.

SOURCE Werfen

Subsidiaries ALIF Holding and Neurovia AI to present visual data technology and outline plans for maritime systems and advanced materials at Stand AH5D

DUBAI, UAE, Nov. 12, 2026 /PRNewswire/ — Robo.ai Inc. (Nasdaq: AIIO) (“Robo.ai” or the “Company”) today announced that its controlled subsidiary ALIF Holding, an Abu Dhabi-based industrial group, together with Neurovia AI, another subsidiary of the Company, will participate in the World Police Summit on November 16–18, 2026, at the Dubai World Trade Centre. Participation in the Summit supports the Company’s strategy of bringing AI infrastructure and local industrial capabilities to government, public safety and mission-critical sectors in the UAE and wider Middle East.

Hosted by Dubai Police and organized by DXB LIVE, the Summit is a major Middle East platform that brings together international law enforcement leaders, public safety decision-makers and technology companies. Its fifth edition, themed “Connected for Impact,” offers Robo.ai a focused opportunity to engage with prospective customers and technology partners on their operational needs.

At Stand AH5D, Neurovia AI will present NeuroStream™, its visual data optimization platform designed to reduce video storage and transmission requirements while preserving information needed for downstream applications. In a previously reported demonstration, a 12.15 GB, 4K video file was reduced to 421 MB, a decrease of more than 96%. This result reflects a specific demonstration; actual performance and benefits depend on deployment conditions and use-case validation.

ALIF Holding will also outline plans for intelligent maritime systems for ports, coastlines and critical facilities through the proposed ALIF Maritec, and for carbon fiber materials and UAE manufacturing capabilities through the proposed ALIF Composites. Together, these initiatives reflect Robo.ai’s strategy of connecting efficient AI data infrastructure with intelligent systems and local industrial development.

This approach aligns with the UAE National Strategy for Artificial Intelligence 2031 and the technology-enabled public safety ambitions of “We the UAE 2031.” At the Summit, Robo.ai aims to deepen customer engagement and develop partnerships that can support commercial applications and long-term business growth.

About ALIF Holding

ALIF Holding is Robo.ai’s Abu Dhabi-based industrial group, focused on intelligent software, intelligent equipment and the development of local industrial capabilities. Through international technology collaboration and local integration, it aims to develop intelligent systems and products for governments, critical infrastructure and industrial customers.

About Neurovia AI

Neurovia AI is an Abu Dhabi-headquartered artificial intelligence infrastructure and visual data processing company, operating as a wholly owned subsidiary of Robo.ai Inc. (Nasdaq: AIIO).Through its flagship platform, NeuroStream™, the company develops intelligent data optimization solutions designed to reduce infrastructure demands while supporting efficient, secure and scalable AI applications.Neurovia AI serves the evolving needs of government, enterprise and data-intensive industries, advancing its vision of scaling sustainable AI infrastructure.

About Robo.ai Inc.

Robo.ai Inc. (Nasdaq: AIIO), headquartered in Dubai, United Arab Emirates, is a Nasdaq-listed technology group building intelligent infrastructure across four platforms: artificial intelligence; robotics and smart mobility; advanced manufacturing; and digital assets and capital. Its industrial group, ALIF Holding, is dedicated to building intelligent industries through the development, integration and manufacturing of AI systems, serving government, public sector and mission-critical domains. Through its subsidiary Neurovia AI, the Company develops AI software and visual data infrastructure. Quantum Core Capital (“QC Capital”), its AI-powered deep-tech holding and venture-building platform, incubates, invests in and operates businesses across artificial intelligence, robotics, digital infrastructure and the next-generation digital economy.

Forward-Looking Statements

This release includes forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995 concerning exhibition plans, technology benefits, proposed projects, local manufacturing, partnerships and business growth. These statements reflect current expectations and are not guarantees of future performance. Actual outcomes may differ materially due to technology validation and commercialization, customer demand, competition, funding, project formation, permits, equipment, site readiness and execution risks, as well as the Company’s financial condition and other risks described in its SEC filings. Proposed projects remain subject to development and operational readiness. These statements speak only as of the date of this release, and, except as required by applicable law, Robo.ai undertakes no obligation to update or revise them.

Media Contacts

ALIF Holding Corporate Communications
Email: info@alifholding.ai  |  Website: www.alifholding.ai

Neurovia AI | Marketing & Communications
Email: info@neuroviaai.com Website: www.neuroviaai.com

Robo.ai Inc. Corporate Communications
Email: pr@roboai.group  |  Website: www.roboai.group

View original content to download multimedia:https://www.prnewswire.com/news-releases/roboai-to-advance-its-middle-east-public-safety-strategy-at-world-police-summit-2026-302937724.html

SOURCE Robo.ai Inc.

CodeWall is scaling its engineering team and autonomous attack platform with an ambition to make offensive security as fundamental as firewalls and endpoint protection.

LONDON, Nov. 12, 2026 /PRNewswire/ — CodeWall is accelerating its expansion to make autonomous offensive security a permanent enterprise capability. Following its $4 million pre-seed round, the company is scaling engineering and expanding what its autonomous attack agents can investigate, today announcing former Orca Security VP of Engineering Peter Spellward as Chief Technology Officer to lead that effort.

Spellward brings experience building security technology and the organisations behind it. At cloud security unicorn Orca Security, he served as VP of Engineering, led UK research and development and helped scale its engineering organisation. He also co-founded Innovode, whose technology was acquired by CloudLock, subsequently acquired by Cisco.

“AI is giving attackers extraordinary speed and reach. We’re building to put that advantage in the hands of enterprise security teams,” said Paul Price, founder and CEO of CodeWall. “We intend to move aggressively: hire exceptional engineers, expand what our agents can take on and bring this capability to more enterprises. Peter brings experience building the products and engineering organisations that make that expansion possible.”

Spellward leads technology strategy and engineering, with a focus on accelerating delivery, broadening platform coverage and strengthening how agents coordinate complex investigations.

“The engineering challenge is to turn sophisticated attacker behaviour into a capability enterprises can depend on continuously,” said Peter Spellward, CTO of CodeWall. “That means agents that can safely reason through unfamiliar systems, build on each other’s discoveries and produce evidence defenders can trust. We’re building the team and architecture to deliver that at scale.”

CodeWall’s agents investigate enterprise environments from an external attacker’s perspective. They share discoveries and follow weaknesses across connected systems to establish what could actually be compromised, supporting continued investigation and retesting as customer environments change.

The company is already working with large banks and fintech firms, including Axos Financial, to deliver autonomous offensive testing and verified evidence of exploitable attack paths.

“Every enterprise will have an attacker working for it. It will be as essential as a firewall or endpoint protection,” added Price. “We intend to make CodeWall the standard. That’s the scale we’re hiring for, building for and going after.”

To learn more or explore open roles, visit codewall.ai.

About CodeWall

CodeWall builds autonomous offensive security technology for enterprises. Its agents investigate externally accessible systems, trace exploitable weaknesses and provide verified evidence to help defenders address their exposure. The platform supports sustained adversarial testing within customer-defined guardrails.

Media Contact:
press@codewall.ai

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/codewall-accelerates-expansion-names-former-orca-security-vp-as-cto-302937370.html